Education ▼

PER is hosting the 2nd Annual International Congress on Oncology Pathology^™ | June 23rd in NYC Hematologic Malignancies Medical Crossfire in NYC on July 14th! Register today!

SPECIALTY TOPICS

CURRENTLY VIEWING
Chronic Lymphocytic Leukemia

Gastrointestinal Cancer

Chronic Lymphocytic Leukemia

Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma

Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.
Read More >>

2018 EHA: Upfront Duvelisib Plus FCR Shows Promise in Younger Patients With CLL

2018 EHA: Obinutuzumab/Chlorambucil Solidified as Frontline CLL Option

FDA Grants Venetoclax Full Approval for CLL, Regardless of 17p Deletion

ASCO 2018: Frontline Ibrutinib/Venetoclax Combo Shows High MRD-Negative Responses for CLL

Frontline Ibrutinib Plus Obinutuzumab Improves PFS in Phase III CLL Trial

View More Stories >>

View Conference Coverage

2018 World Congress on GI Cancer

2018 European Hematology Association Congress

2018 State of the Science Summit on Genitourinary Cancers

2018 ASCO Annual Meeting

2018 ASPHO Conference

$Dr. Davids Discusses Duvelisib in Relapsed/Refractory CLL$

Dr. Davids Discusses Duvelisib in Relapsed/Refractory CLL

Dr. Jacobs Discusses the Frontline Treatment of CLL

Dr. Skarbnik Discusses the Changing Landscape of CLL

Dr. Byrd Discusses the Prognosis of Patients With CLL

Dr. Jacobs on the Use of Ibrutinib in High-Risk Patients With CLL

Dr. Kay Discusses Combination Strategies in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Evaluating CAR T-Cell Therapy Use

The Role of Transplant and Future of CLL

Other Promising Strategies in CLL

Maintenance and Frontline Therapy in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

The Evolving Treatment Landscape of CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

Relapsed/Refractory CLL: Evaluating Other Novel Agents

$Novel Approaches to Treating Relapsed/Refractory CLL$

Novel Approaches to Treating Relapsed/Refractory CLL

$Continuing Therapy in Relapsed/Refractory CLL$

$Evaluating Pharmacologic Agents in Relapsed/Refractory CLL$

CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

$Approaching Therapy for Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Other Promising Strategies in CLL

This expert panel discussion led by William Wierda, MD, focuses on promising strategies available for the treatment of chronic lymphocytic leukemia. Dr. Wierda is joined in this discussion by Steven Coutre, MD; Matthew S. Davids, MD, MMSc; Nicole Lamanna, MD; and Shuo Ma, MD, PhD.

View Now

The Use of Novel PI3K Inhibitors in CLL

In this segment William Wierda, MD, PhD, leads a panel discussion regarding the use of novel PI3K inhibitors in chronic lymphocytic leukemia.

View Now

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approvals in Cervical Cancer, Ovarian Cancer, and CLL, and More